ReviewMolecular imaging and biology2025
Nanophotonics in Molecular Imaging and Biomedicine: Diagnostics, Therapies, and Translational Challenges.
Review in Molecular imaging and biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanophotonics-the manipulation of light at the nanometer scale within biological systems-is transforming molecular imaging and photobiology, enabling advanced in vivo imaging, diagnostics, and therapy guidance. This review outlines core nanophotonic principles, including surface plasmon resonance, optical confinement, and photon-matter interactions, underpinning emerging molecular imaging probes and diagnostic tools. Biocompatible nanomaterials such as quantum dots, gold nanoparticles, and photonic metamaterials enable highly sensitive, selective imaging and biosensing for early, minimally invasive disease detection and monitoring. Targeted photothermal and photodynamic therapies using near-infrared (NIR) and NIR-II light advance image-guided interventions, allowing deeper tissue penetration with minimal collateral damage. We also discuss the integration of nanophotonic components into lab-on-a-chip and microfluidic platforms for point-of-care diagnostics, accelerating clinical translation. Additionally, machine learning enhances molecular imaging analysis and probe optimization, enabling real-time data interpretation and predictive modeling tailored to patient-specific profiles. This article is a narrative review that emphasizes recent advancements from 2021-2025, identified through targeted database searches, highlighting progress, research gaps, and future perspectives for disease-specific applications. While these advances hold promise, challenges remain in biocompatibility, light penetration, scalability, and regulatory approval. Collectively, integrating nanophotonics with molecular imaging, machine learning, and personalized medicine frameworks marks a step toward next-generation precision diagnostics and image-guided therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.